U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Neuroblastoma

MedGen UID:
1613939
•Concept ID:
C4525059
•
Neoplastic Process

Definition

A neuroblastoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Neuroblastoma

Professional guidelines

PubMed

Evolution and contemporary role of metronomic chemotherapy in the treatment of neuroblastoma.
Chou SW, Chang HH
Cancer Lett 2024 Apr 28;588:216617. Epub 2024 Feb 2 doi: 10.1016/j.canlet.2024.216617. PMID: 38311055
Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma.
Anongpornjossakul Y, Sriwatcharin W, Thamnirat K, Chamroonrat W, Kositwattanarerk A, Utamakul C, Sritara C, Chokesuwattanasakul P, Thokanit NS, Pakakasama S, Anurathapan U, Pongphitcha P, Chotipanich C, Hongeng S
Nucl Med Commun 2020 Apr;41(4):336-343. doi: 10.1097/MNM.0000000000001152. PMID: 31939898
Treatment and outcome of adult-onset neuroblastoma.
Suzuki M, Kushner BH, Kramer K, Basu EM, Roberts SS, Hammond WJ, LaQuaglia MP, Wolden SL, Cheung NV, Modak S
Int J Cancer 2018 Sep 1;143(5):1249-1258. Epub 2018 Apr 6 doi: 10.1002/ijc.31399. PMID: 29574715Free PMC Article

Recent clinical studies

Etiology

CD146 is a potential immunotarget for neuroblastoma.
Obu S, Umeda K, Ueno H, Sonoda M, Tasaka K, Ogata H, Kouzuki K, Nodomi S, Saida S, Kato I, Hiramatsu H, Okamoto T, Ogawa E, Okajima H, Morita K, Kamikubo Y, Kawaguchi K, Watanabe K, Iwafuchi H, Yagyu S, Iehara T, Hosoi H, Nakahata T, Adachi S, Uemoto S, Heike T, Takita J
Cancer Sci 2021 Nov;112(11):4617-4626. Epub 2021 Sep 30 doi: 10.1111/cas.15124. PMID: 34464480Free PMC Article
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, Villablanca JG, Vo KT, Pinto N, Mosse YP, Maris JM, Shusterman S, Cohn SL, Goldsmith KC, Weiss B, Yanik GA, Twist CJ, Irwin MS, Haas-Kogan DA, Park JR, Marachelian A, Matthay KK
J Clin Oncol 2021 Nov 1;39(31):3506-3514. Epub 2021 Jul 16 doi: 10.1200/JCO.21.00703. PMID: 34270348Free PMC Article
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R
J Clin Oncol 2020 Jul 1;38(19):2160-2169. Epub 2020 Apr 28 doi: 10.1200/JCO.20.00203. PMID: 32343642Free PMC Article
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R
Lancet Oncol 2017 Jul;18(7):946-957. Epub 2017 May 23 doi: 10.1016/S1470-2045(17)30355-8. PMID: 28549783Free PMC Article
Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review.
Kushner BH, Cheung NK, Kramer K, Heller G, Jhanwar SC
J Clin Oncol 1998 Dec;16(12):3880-9. doi: 10.1200/JCO.1998.16.12.3880. PMID: 9850034

Diagnosis

Translational Strategies for Repotrectinib in Neuroblastoma.
O'Donohue TJ, Ibáñez G, Coutinho DF, Mauguen A, Siddiquee A, Rosales N, Calder P, Ndengu A, You D, Long M, Roberts SS, Kung AL, Dela Cruz FS
Mol Cancer Ther 2021 Nov;20(11):2189-2197. Epub 2021 Sep 4 doi: 10.1158/1535-7163.MCT-21-0126. PMID: 34482287Free PMC Article
Treatment and outcome of adult-onset neuroblastoma.
Suzuki M, Kushner BH, Kramer K, Basu EM, Roberts SS, Hammond WJ, LaQuaglia MP, Wolden SL, Cheung NV, Modak S
Int J Cancer 2018 Sep 1;143(5):1249-1258. Epub 2018 Apr 6 doi: 10.1002/ijc.31399. PMID: 29574715Free PMC Article
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R
Lancet Oncol 2017 Jul;18(7):946-957. Epub 2017 May 23 doi: 10.1016/S1470-2045(17)30355-8. PMID: 28549783Free PMC Article
131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma.
DuBois SG, Matthay KK
Q J Nucl Med Mol Imaging 2013 Mar;57(1):53-65. PMID: 23474635
Disialoganglioside directed immunotherapy of neuroblastoma.
Modak S, Cheung NK
Cancer Invest 2007 Feb;25(1):67-77. doi: 10.1080/07357900601130763. PMID: 17364560

Therapy

Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LS
Nat Med 2023 Jun;29(6):1379-1388. Epub 2023 May 15 doi: 10.1038/s41591-023-02363-y. PMID: 37188782
Translational Strategies for Repotrectinib in Neuroblastoma.
O'Donohue TJ, Ibáñez G, Coutinho DF, Mauguen A, Siddiquee A, Rosales N, Calder P, Ndengu A, You D, Long M, Roberts SS, Kung AL, Dela Cruz FS
Mol Cancer Ther 2021 Nov;20(11):2189-2197. Epub 2021 Sep 4 doi: 10.1158/1535-7163.MCT-21-0126. PMID: 34482287Free PMC Article
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, Chauvin-Fleurence CN, Xu X, Ngai H, Di Pierro EJ, Savoldo B, Dotti G, Metelitsa LS
Nat Med 2020 Nov;26(11):1686-1690. Epub 2020 Oct 12 doi: 10.1038/s41591-020-1074-2. PMID: 33046868
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R
J Clin Oncol 2020 Jul 1;38(19):2160-2169. Epub 2020 Apr 28 doi: 10.1200/JCO.20.00203. PMID: 32343642Free PMC Article
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R
Lancet Oncol 2017 Jul;18(7):946-957. Epub 2017 May 23 doi: 10.1016/S1470-2045(17)30355-8. PMID: 28549783Free PMC Article

Prognosis

CD146 is a potential immunotarget for neuroblastoma.
Obu S, Umeda K, Ueno H, Sonoda M, Tasaka K, Ogata H, Kouzuki K, Nodomi S, Saida S, Kato I, Hiramatsu H, Okamoto T, Ogawa E, Okajima H, Morita K, Kamikubo Y, Kawaguchi K, Watanabe K, Iwafuchi H, Yagyu S, Iehara T, Hosoi H, Nakahata T, Adachi S, Uemoto S, Heike T, Takita J
Cancer Sci 2021 Nov;112(11):4617-4626. Epub 2021 Sep 30 doi: 10.1111/cas.15124. PMID: 34464480Free PMC Article
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, Villablanca JG, Vo KT, Pinto N, Mosse YP, Maris JM, Shusterman S, Cohn SL, Goldsmith KC, Weiss B, Yanik GA, Twist CJ, Irwin MS, Haas-Kogan DA, Park JR, Marachelian A, Matthay KK
J Clin Oncol 2021 Nov 1;39(31):3506-3514. Epub 2021 Jul 16 doi: 10.1200/JCO.21.00703. PMID: 34270348Free PMC Article
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R
J Clin Oncol 2020 Jul 1;38(19):2160-2169. Epub 2020 Apr 28 doi: 10.1200/JCO.20.00203. PMID: 32343642Free PMC Article
Treatment and outcome of adult-onset neuroblastoma.
Suzuki M, Kushner BH, Kramer K, Basu EM, Roberts SS, Hammond WJ, LaQuaglia MP, Wolden SL, Cheung NV, Modak S
Int J Cancer 2018 Sep 1;143(5):1249-1258. Epub 2018 Apr 6 doi: 10.1002/ijc.31399. PMID: 29574715Free PMC Article
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R
Lancet Oncol 2017 Jul;18(7):946-957. Epub 2017 May 23 doi: 10.1016/S1470-2045(17)30355-8. PMID: 28549783Free PMC Article

Clinical prediction guides

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, Chauvin-Fleurence CN, Xu X, Ngai H, Di Pierro EJ, Savoldo B, Dotti G, Metelitsa LS
Nat Med 2020 Nov;26(11):1686-1690. Epub 2020 Oct 12 doi: 10.1038/s41591-020-1074-2. PMID: 33046868
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R
J Clin Oncol 2020 Jul 1;38(19):2160-2169. Epub 2020 Apr 28 doi: 10.1200/JCO.20.00203. PMID: 32343642Free PMC Article
Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma.
Anongpornjossakul Y, Sriwatcharin W, Thamnirat K, Chamroonrat W, Kositwattanarerk A, Utamakul C, Sritara C, Chokesuwattanasakul P, Thokanit NS, Pakakasama S, Anurathapan U, Pongphitcha P, Chotipanich C, Hongeng S
Nucl Med Commun 2020 Apr;41(4):336-343. doi: 10.1097/MNM.0000000000001152. PMID: 31939898
Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.
Tran HC, Marachelian A, Venkatramani R, Jubran RF, Mascarenhas L
Pediatr Hematol Oncol 2015 Feb;32(1):26-31. Epub 2014 Dec 31 doi: 10.3109/08880018.2014.983624. PMID: 25551355
Disialoganglioside directed immunotherapy of neuroblastoma.
Modak S, Cheung NK
Cancer Invest 2007 Feb;25(1):67-77. doi: 10.1080/07357900601130763. PMID: 17364560

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...